Arovella Therapeutics Ltd (ASX: ALA) Share Price and News

Dr Nash has over 35 years of practical drug development experience and executive leadership in the biotech and pharmaceutical sector. Dr Nash initially trained as an academic scientist. He then joined Zenyth (formerly Amrad Corp), where he advanced to become Chief Scientific Officer (CSO), and ultimately CEO before it was sold to CSL in 2006. Dr Nash was appointed CSO of CSL in 2020 and remained in that position until his retirement in March 2025. Dr Nash has had a career, being elected as a Fellow of the Academy of Technological Sciences and Engineering in 2021, and as a Fellow of the Australian Academy of Science in 2025. He was the inaugural Chair of Jumar Bioincubator and is currently a Board Director at the Burnet Institute, the Garvan Institute of Medical Research, Brandon BioCatalyst and Denteric.

Mr Phillips has more than 40 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. After managing country operations for Novartis in Eastern Europe and Asia, Gary came to Australia as CEO of Novartis in 2001, launching leading oncology and ophthalmology products. Following his appointment as Pharmaxis CEO in 2013, Gary oversaw a company restructure focused on building value, forging commercial partnerships and fostering the development of the Pharmaxis product pipeline. Gary has recently led the further restructuring of Pharmaxis with the sale of commercial assets and manufacturing facility, enabling the renamed company Syntara to focus on its pipeline of clinical stage assets in oncology, fibrosis and inflammation.

Dr Baker has over 20 years of experience in scientific research, drug development and venture investment. He was an Investment Manager with Australian life science fund, BioScience Managers, responsible for deal sourcing from networks, conferences, universities, and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies.

Dr Barton has over 20 years of oncology experience, which includes 9 years of clinical management of oncology patients and enrolling patients in clinical trials in academia. In the pharmaceutical industry, she has experience in medical affairs and clinical development in both large pharmaceutical and small biotech companies, including regulatory interactions in the USA, Europe, Australia, and several countries around the world. She has undertaken an oncology product submission and subsequent marketing authorisation in the US and Europe and has built innovative clinical development plans coupled with clinical/safety teams' infrastructure in small biotech.

Dr Stoner has over 30 years of experience in the life-science sector. She is currently an executive partner at MPM Capital, a US healthcare investment firm. In her role, Dr Stoner serves as a clinical advisor to several of MPM Capital's portfolio companies, including Antiva, and Rhythm Pharmaceuticals. Additionally, Dr Stoner served as the interim CEO of Semma Therapeutics. Prior to joining MPM Capital, Dr Stoner was a Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries.

-

-

-